Bloodstream Infection Testing Market Forecasts to 2034 – Global Analysis By Product Type (Instruments, Consumables and Software), By Pathogen Type (Bacterial Bloodstream Infections, Fungal Bloodstream Infections and Viral Bloodstream Infections), Testing, Technology, End User and By Geography

May 2026 | 200 pages | ID: BAD87A552863EN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Bloodstream Infection Testing Market is accounted for $7.9 billion in 2026 and is expected to reach $16.1 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Bloodstream infection testing involves diagnostic procedures aimed at identifying microbial pathogens in the bloodstream. This testing utilizes various techniques, including blood cultures and molecular methods, to detect bacteria, viruses, or fungi causing systemic infections. It plays a crucial role in early identification, guiding appropriate treatment decisions and preventing the spread of infections, significantly impacting patient care and public health on a worldwide scale.

According to the U.S. National Library of Medicine, world’s largest medical library, Bloodstream Infections (BSIs) are a leading global cause of disease and mortality. The incidence of BSIs has grown over time and the rates ranges from 122 to 220 cases per 100,000 people.

Market Dynamics:

Driver:

Rising cases of bloodstream infections worldwide

The alarming rise in bloodstream infections (BSIs) across the globe is acting as a potent fuel for the bloodstream infection testing market. This surge is attributed to factors like increasing antibiotic resistance, invasive medical procedures and an aging population that is more susceptible to infections. This growing demand for rapid and precise identification of causative pathogens is driving the market for advanced diagnostic technologies like rapid molecular tests and automated blood culture systems. Additionally, heightened awareness about healthcare-associated infections (HAIs) is prompting hospitals and clinics to invest in robust BSI testing protocols, further propelling the market's expansion.

Restraint:

High costs associated with advanced diagnostic technologies

Advanced diagnostic technologies offer faster and more accurate bloodstream infection testing, their high price tag acts as a major market restraint. These sophisticated tests often require expensive equipment, specialized technicians, and complex workflows, driving up costs for both healthcare providers and patients. This can limit their accessibility in resource-constrained settings and discourage their widespread adoption, hindering the potential benefits they bring to patient care.

Opportunity:

Awareness among healthcare professionals

A crucial opportunity lies in raising awareness among healthcare professionals within the bloodstream infection testing market. Currently, many practitioners lack sufficient knowledge about the latest testing methods or the urgency of early BSI detection. By educating doctors, nurses and other medical staff on the rapid identification and treatment benefits of advanced testing, the market can unlock significant growth potential, which can effectively tap into this lucrative opportunity and drive market expansion.

Threat:

Data security concerns

Bloodstream infection testing relies heavily on digital data, making it vulnerable to cyberattacks. Hackers could steal sensitive patient information or manipulate test results, impacting diagnoses and potentially harming patients. This raises concerns about data privacy, trust in test accuracy and potential legal repercussions that limit market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted bloodstream infection testing. Medical facilities faced challenges in prioritizing resources for COVID-19 testing, potentially reducing attention to routine testing for bloodstream infections. Additionally, infection control measures, increased patient loads, and altered healthcare practices strained laboratory capacities. Delayed or reduced testing for bloodstream infections during the pandemic might have affected timely diagnosis and treatment, potentially impacting patient outcomes and necessitating adaptations in testing strategies and healthcare delivery.

The instrument segment is expected to be the largest during the forecast period

The instrument segment is poised to secure the largest market share in the market due to the increasing prevalence of bloodstream infections. Automated blood culture systems, molecular diagnostic platforms, and mass spectrometers play pivotal roles in identifying pathogens swiftly. Additionally, continuous advancements in instrument technologies, such as improved sensitivity and specificity, bolster their prominence, making them the leading contributor to the market share for bloodstream infection testing.

The diagnostics laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics laboratories segment is poised for significant growth due to increased awareness of preventive healthcare and amplified demand for diagnostic services. Technological advancements in diagnostics have led to more accurate and efficient testing methods, attracting more patients. Additionally, the rising prevalence of chronic diseases necessitates regular monitoring, boosting the need for diagnostic center services. Moreover, the COVID-19 pandemic emphasized the importance of accessible and efficient diagnostic facilities, fostering the expansion of diagnostics centers globally.

Region with largest share:

North America's dominance in the bloodstream infection testing market is owing to its advanced healthcare infrastructure and significant investments in research and development. Moreover, the presence of key market players, collaborations between industry and research institutions, and robust regulatory frameworks contribute to market growth. Additionally, the region's proactive adoption of innovative diagnostic technologies and heightened awareness about the importance of infection control further solidify North America's position in securing the largest market share.

Region with highest CAGR:

The Asia-Pacific region is positioned for significant growth due to rapid urbanization, increasing healthcare spending and expanding access to advanced medical technologies. Additionally, a growing population, rising awareness about health issues, and government initiatives supporting healthcare infrastructure development contribute to this trajectory. With a burgeoning middle class and evolving healthcare systems, the Asia-Pacific region presents immense opportunities for market expansion across various industries, including healthcare and diagnostics.

Key players in the market

Some of the key players in Bloodstream Infection Testing Market include Abbott Laboratories, Accelerate Diagnostics, Becton, Dickinson and Company (BD), Biocartis, BioM?rieux, Bio-Rad Laboratories, Bruker Corporation, Cepheid, Danaher Corporation, DiaSorin, GenMark Diagnostics, Grifols, Hologic, Inc., Luminex Corporation, Molzym, OpGen, Qiagen, Roche Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.

Key Developments:

In October 2023, Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis’ worldwide commercial network.

In October 2023, Oxford Nanopore Technologies plc (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioM?rieux SA, a world leader in the field of in vitro diagnostics (“IVD”) announced that bioM?rieux is making an immediate ?70M investment in Oxford Nanopore.

Product Types Covered:

• Instruments
• Consumables
• Services

Pathogen Types Covered:

• Bacterial Bloodstream Infections
• Fungal Bloodstream Infections
• Viral Bloodstream Infections

Testings Covered:

• Blood Culture Test
• Molecular Diagnostics
• Microbiological Testing
• Immunological Testing

Technologies Covered:

• Conventional Culture Technology
• Mass Spectrometry
• Microarray Technology
• Next-Generation Sequencing (NGS)
• Other Technologies

End Users Covered:

• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Point-of-Care Testing
• Other End Users

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• UK
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• South Korea
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
• Comprehensive profiling of additional market players (up to 3)
• SWOT Analysis of key players (up to 3)
• Regional Segmentation
• Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 End User Analysis
3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY PRODUCT TYPE

5.1 Introduction
5.2 Instruments
  5.2.1 Automated Blood Culture Systems
  5.2.2 Polymerase Chain Reaction (PCR) Instruments
5.3 Consumables
  5.3.1 Blood Culture Bottles
  5.3.2 Reagents
5.4 Software
  5.4.1 Data Analysis Software
  5.4.2 Reporting and Interpretation Software

6 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY PATHOGEN TYPE

6.1 Introduction
6.2 Bacterial Bloodstream Infections
6.3 Fungal Bloodstream Infections
6.4 Viral Bloodstream Infections

7 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY TESTING

7.1 Introduction
7.2 Blood Culture Test
  7.2.1 Conventional Blood Culture
  7.2.2 Automated Blood Culture
7.3 Molecular Diagnostics
  7.3.1 Polymerase Chain Reaction (PCR)
  7.3.2 Nucleic Acid Amplification Techniques (NAAT)
7.4 Microbiological Testing
7.5 Immunological Testing

8 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY TECHNOLOGY

8.1 Introduction
8.2 Conventional Culture Technology
8.3 Mass Spectrometry
8.4 Microarray Technology
8.5 Next-Generation Sequencing (NGS)
8.6 Other Technologies

9 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY END USER

9.1 Introduction
9.2 Hospitals and Clinics
9.3 Diagnostic Laboratories
9.4 Academic and Research Institutes
9.5 Point-of-Care Testing
9.6 Other End Users

10 GLOBAL BLOODSTREAM INFECTION TESTING MARKET, BY GEOGRAPHY

10.1 Introduction
10.2 North America
  10.2.1 US
  10.2.2 Canada
  10.2.3 Mexico
10.3 Europe
  10.3.1 Germany
  10.3.2 UK
  10.3.3 Italy
  10.3.4 France
  10.3.5 Spain
  10.3.6 Rest of Europe
10.4 Asia Pacific
  10.4.1 Japan
  10.4.2 China
  10.4.3 India
  10.4.4 Australia
  10.4.5 New Zealand
  10.4.6 South Korea
  10.4.7 Rest of Asia Pacific
10.5 South America
  10.5.1 Argentina
  10.5.2 Brazil
  10.5.3 Chile
  10.5.4 Rest of South America
10.6 Middle East & Africa
  10.6.1 Saudi Arabia
  10.6.2 UAE
  10.6.3 Qatar
  10.6.4 South Africa
  10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 COMPANY PROFILING

12.1 Abbott Laboratories
12.2 Accelerate Diagnostics
12.3 Becton, Dickinson and Company (BD)
12.4 Biocartis
12.5 BioM?rieux
12.6 Bio-Rad Laboratories
12.7 Bruker Corporation
12.8 Cepheid
12.9 Danaher Corporation
12.10 DiaSorin
12.11 GenMark Diagnostics
12.12 Grifols
12.13 Hologic, Inc.
12.14 Luminex Corporation
12.15 Molzym
12.16 OpGen
12.17 Qiagen
12.18 Roche Diagnostics
12.19 Sysmex Corporation
12.20 Thermo Fisher Scientific

List Of Tables

LIST OF TABLES

Table 1 Global Bloodstream Infection Testing Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Bloodstream Infection Testing Market Outlook, By Product Type (2023-2034) ($MN)
Table 3 Global Bloodstream Infection Testing Market Outlook, By Instruments (2023-2034) ($MN)
Table 4 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture Systems (2023-2034) ($MN)
Table 5 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2023-2034) ($MN)
Table 6 Global Bloodstream Infection Testing Market Outlook, By Consumables (2023-2034) ($MN)
Table 7 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Bottles (2023-2034) ($MN)
Table 8 Global Bloodstream Infection Testing Market Outlook, By Reagents (2023-2034) ($MN)
Table 9 Global Bloodstream Infection Testing Market Outlook, By Software (2023-2034) ($MN)
Table 10 Global Bloodstream Infection Testing Market Outlook, By Data Analysis Software (2023-2034) ($MN)
Table 11 Global Bloodstream Infection Testing Market Outlook, By Reporting and Interpretation Software (2023-2034) ($MN)
Table 12 Global Bloodstream Infection Testing Market Outlook, By Pathogen Type (2023-2034) ($MN)
Table 13 Global Bloodstream Infection Testing Market Outlook, By Bacterial Bloodstream Infections (2023-2034) ($MN)
Table 14 Global Bloodstream Infection Testing Market Outlook, By Fungal Bloodstream Infections (2023-2034) ($MN)
Table 15 Global Bloodstream Infection Testing Market Outlook, By Viral Bloodstream Infections (2023-2034) ($MN)
Table 16 Global Bloodstream Infection Testing Market Outlook, By Testing (2023-2034) ($MN)
Table 17 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Test (2023-2034) ($MN)
Table 18 Global Bloodstream Infection Testing Market Outlook, By Conventional Blood Culture (2023-2034) ($MN)
Table 19 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture (2023-2034) ($MN)
Table 20 Global Bloodstream Infection Testing Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
Table 21 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
Table 22 Global Bloodstream Infection Testing Market Outlook, By Nucleic Acid Amplification Techniques (NAAT) (2023-2034) ($MN)
Table 23 Global Bloodstream Infection Testing Market Outlook, By Microbiological Testing (2023-2034) ($MN)
Table 24 Global Bloodstream Infection Testing Market Outlook, By Immunological Testing (2023-2034) ($MN)
Table 25 Global Bloodstream Infection Testing Market Outlook, By Technology (2023-2034) ($MN)
Table 26 Global Bloodstream Infection Testing Market Outlook, By Conventional Culture Technology (2023-2034) ($MN)
Table 27 Global Bloodstream Infection Testing Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
Table 28 Global Bloodstream Infection Testing Market Outlook, By Microarray Technology (2023-2034) ($MN)
Table 29 Global Bloodstream Infection Testing Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
Table 30 Global Bloodstream Infection Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
Table 31 Global Bloodstream Infection Testing Market Outlook, By End User (2023-2034) ($MN)
Table 32 Global Bloodstream Infection Testing Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
Table 33 Global Bloodstream Infection Testing Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
Table 34 Global Bloodstream Infection Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
Table 35 Global Bloodstream Infection Testing Market Outlook, By Point-of-Care Testing (2023-2034) ($MN)
Table 36 Global Bloodstream Infection Testing Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.